Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings (NQ: BPTH )

0.7990 +0.0113 (+1.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bio-Path Holdings

< Previous 1 2 3 4 5 6 Next >
Earnings Scheduled For November 15, 2024
Via Benzinga
Uncovering Potential: Bio-Path Holdings's Earnings Preview
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Nasdaq Surges Over 1%; DocuSign Shares Spike Higher
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Looking Into Bio-Path Hldgs's Recent Short Interest
Via Benzinga
Crude Oil Falls Over 4%; US Trade Deficit Narrows In August
Via Benzinga
Exposures Fossil Fuels
US Stocks Edge Higher; PepsiCo Cuts 2024 Revenue Outlook
Via Benzinga
ACHR, BPTH, PLUG, REGRF:
Leaders Report Latest Advances 
Via News Direct
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
What Happened With Bio-Path Stock Today?
Bio-Path shares ended Wednesday's session slightly higher after the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A. 
Via Benzinga
BPTH Stock Earnings: Bio-Path Holdings Beats EPS for Q2 2024
BPTH stock results show that Bio-Path Holdings beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning! 
Via InvestorPlace
Onsemi Layoffs 2024: What to Know as Onsemi Cuts 1,000 Jobs
Onsemi layoffs are a hot topic on Friday after the company announced plans to cut jobs and close down some of its sites on weak demand. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Bank of America Thinks Hasbro (HAS) Stock Can Gain 40% From Here
Hasbro stock is up on Friday with a price target increase and rating upgrade for HAS shares from Bank of America analsyts. 
Via InvestorPlace
Why Is Bio-Path (BPTH) Stock Up 20% Today?
Bio-Path stock is up on Friday with heavy trading of NPTH shares after the company posited positive interim data from a Phase 2 study. 
Via InvestorPlace
Why Bio-Path Stock Is Climbing Today
Bio-Path Holdings shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Dow Dips Over 300 Points; GameStop Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Down Over 3%; US Construction Spending Falls In May
Via Benzinga
Exposures Fossil Fuels
What's Going On With Bio-Path Stock?
Bio-Path Holdings shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and... 
Via Benzinga
Nasdaq Surges 150 Points; US Manufacturing PMI Rises In May
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
BPTH Stock Earnings: Bio-Path Holdings Misses EPS for Q1 2024
BPTH stock results show that Bio-Path Holdings missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.